TY - JOUR
T1 - In vivo visualization of tau deposits in corticobasal syndrome by 18 F-THK5351 PET
AU - Kikuchi, Akio
AU - Okamura, Nobuyuki
AU - Hasegawa, Takafumi
AU - Harada, Ryuichi
AU - Watanuki, Shoichi
AU - Funaki, Yoshihito
AU - Hiraoka, Kotaro
AU - Baba, Toru
AU - Sugeno, Naoto
AU - Oshima, Ryuji
AU - Yoshida, Shun
AU - Kobayashi, Junpei
AU - Ezura, Michinori
AU - Kobayashi, Michiko
AU - Tano, Ohito
AU - Mugikura, Shunji
AU - Iwata, Ren
AU - Ishiki, Aiko
AU - Furukawa, Katsutoshi
AU - Arai, Hiroyuki
AU - Furumoto, Shozo
AU - Tashiro, Manabu
AU - Yanai, Kazuhiko
AU - Kudo, Yukitsuka
AU - Takeda, Atsushi
AU - Aoki, Masashi
N1 - Publisher Copyright:
© 2016 American Academy of Neurology.
PY - 2016/11/29
Y1 - 2016/11/29
N2 - Objective: To determine whether 18 F-THK5351 PET can be used to visualize tau deposits in brain lesions in live patients with corticobasal syndrome (CBS). Methods: We evaluated the in vitro binding of 3 H-THK5351 in postmortem brain tissues from a patient with corticobasal degeneration (CBD). In clinical PET studies, 18 F-THK5351 retention in 5 patients with CBS was compared to that in 8 age-matched normal controls and 8 patients with Alzheimer disease (AD). Results: 3 H-THK5351 was able to bind to tau deposits in the postmortem brain with CBD. In clinical PET studies, the 5 patients with CBS showed significantly higher 18 F-THK5351 retention in the frontal, parietal, and globus pallidus than the 8 age-matched normal controls and patients with AD. Higher 18 F-THK5351 retention was observed contralaterally to the side associated with greater cortical dysfunction and parkinsonism. Conclusions: 18 F-THK5351 PET demonstrated high tracer signal in sites susceptible to tau deposition in patients with CBS. 18 F-THK5351 should be considered as a promising candidate radiotracer for the in vivo imaging of tau deposits in CBS.
AB - Objective: To determine whether 18 F-THK5351 PET can be used to visualize tau deposits in brain lesions in live patients with corticobasal syndrome (CBS). Methods: We evaluated the in vitro binding of 3 H-THK5351 in postmortem brain tissues from a patient with corticobasal degeneration (CBD). In clinical PET studies, 18 F-THK5351 retention in 5 patients with CBS was compared to that in 8 age-matched normal controls and 8 patients with Alzheimer disease (AD). Results: 3 H-THK5351 was able to bind to tau deposits in the postmortem brain with CBD. In clinical PET studies, the 5 patients with CBS showed significantly higher 18 F-THK5351 retention in the frontal, parietal, and globus pallidus than the 8 age-matched normal controls and patients with AD. Higher 18 F-THK5351 retention was observed contralaterally to the side associated with greater cortical dysfunction and parkinsonism. Conclusions: 18 F-THK5351 PET demonstrated high tracer signal in sites susceptible to tau deposition in patients with CBS. 18 F-THK5351 should be considered as a promising candidate radiotracer for the in vivo imaging of tau deposits in CBS.
UR - http://www.scopus.com/inward/record.url?scp=84999873190&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84999873190&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000003375
DO - 10.1212/WNL.0000000000003375
M3 - Article
C2 - 27794115
AN - SCOPUS:84999873190
VL - 87
SP - 2309
EP - 2316
JO - Neurology
JF - Neurology
SN - 0028-3878
IS - 22
ER -